Podcast Summary:

The Digital Executive – Ep. 1101
Title: Redefining Precision Medicine: Tracy Wood on Functional Genomics, Leadership, and Affordable Healthcare Solutions
Release Date: August 19, 2025
Guest: Tracy Wood, CEO of The DNA Company
Host: Brian (Coruzant Technologies)
Duration: ~12 minutes

Overview

This episode features Tracy Wood, CEO of The DNA Company, as she discusses the transformative impact of functional genomics on healthcare, her personal motivation for making medicine safer and more personalized, and her company’s commitment to affordable precision medicine. Tracy shares both personal and professional insights, outlining the future of pharmacogenomics (PGX) testing, the challenges in making it accessible, and new innovations that are poised to accelerate the adoption of personalized care.

Key Discussion Points & Insights

1. Tracy Wood's Defining Moment and Personal Motivation

Timestamp: 01:06–03:26

• Tracy was brought into The DNA Company in mid-2022 to expand their Canadian model into the U.S. market.
• She was drawn to their upcoming pharmacogenomics (PGX) product, which matches medication to patients' genetics to help avoid adverse drug reactions.
• She shared a personal tragedy: her sister Jacque died at age 45 from a drug overdose after a psychiatrist prescribed a complex regimen without adequate genetic or holistic understanding.
• Tracy cited a 2016 Johns Hopkins study showing 250,000–400,000 deaths per year in the U.S. due to preventable medical errors, highlighting how many are medication-related.

Quote:
"My eldest sister Jacque died in 2007 of a drug overdose...that was really a defining moment for me in my own personal life. And from then to now, I've continued on a path of finding, creating, and building affordable solutions so that people like my sister don't have to die so young or through carelessness in a sick care system that's broken."
— Tracy Wood, (02:09)

2. The DNA Company’s Approach to Affordable Precision Medicine

Timestamp: 04:11–05:25

• The company has invested in recruiting top experts in functional genomics and prioritizes a 360-degree view of patient history, genetics, and lifestyle.
• A key tenet: taking time with patients — unlike the norm of seven minutes or less per appointment.
• Focus on treating root causes, not just symptoms, using data-driven insights.
• Deep commitment to meeting patients where they are, and referring out when necessary.

Quote:
"...if we can't meet the patient where they are and help them exact the type of change that they need based on testing, not guessing...we will try to work with that root cause, not just the symptomology."
— Tracy Wood, (04:56)

3. Challenges and Opportunities in Expanding Pharmacogenomics (PGX)

Timestamp: 06:00–08:48

• Despite PGX's roots in research as early as the 1930s, awareness and usage remain limited.
• PGX is “the cornerstone of precision tailored treatment,” but must be paired with functional pathway analysis for full effectiveness.
• Tracy highlights compelling statistics:
  • 3–6% of US hospital admissions are due to PGX failure.
  • PGX testing in large trials has reduced adverse drug reactions by 33%, rehospitalization by 52%, and psychiatric emergencies by ~39%. (Refers to the Elliot trial with nearly 7,000 participants.)
• The company is pushing to drop the cost of PGX tests (often $1,200–$1,300 elsewhere) and make at-home cheek swabbing widely available and affordable.

Quote:
"We really strive to keep ourselves as part of this conversation, making PGX more affordable...we really want anyone that can take a swab into their mouth and do a little cheek swab and send it in in their home to be able to afford it."
— Tracy Wood, (08:17)

4. Innovations and the Future of Functional Genomics

Timestamp: 09:17–11:26

• The DNA Company is expanding their functional genomics reports by adding 40 new genes and their expression patterns in the coming year.
• A unique app delivers newly validated scientific insights to all past and current customers, without requiring additional tests or payment.
• Led by Dr. Krista Kosterman (Chief Science Officer, trained under Dr. Manstur Muhammad), their data analysis algorithms are continually advancing.
• Tracy advocates for moving away from medicine based on aggregate statistics, insisting on data-driven, individualized care as the path forward.
• The company's commitment extends to community education with free resources: webinars, magazines, and regular digital content.

Quote:
"Personalized health can save your life. Precision medicine is the only way we should be practicing. The old ideology of practicing based on aggregate statistics has shown us...that we're killing people and it's unacceptable for any number of people to die prematurely, especially someone like my sister at 45 years old."
— Tracy Wood, (10:25)

Notable Quotes & Memorable Moments

• On her personal ‘why’:
  “I've continued on a path of finding, creating, and building affordable solutions so that people like my sister don't have to die so young or through carelessness in a sick care system that's broken.” (02:23)

• On building patient-centered systems:
  "We built our programs to give these good folks as much time as they really need to feel heard and understood." (04:34)

• On innovation and sharing new science:
  "They can use these new insights and they don’t have to retest, they don’t have to spend any more money, and they don’t have to come out of pocket or be inconvenienced." (09:44)

Timestamps of Important Segments

• 01:06 — Tracy shares her personal story and what drew her to functional genomics.
• 03:26 — Discussion on the scope of preventable medical errors and her motivation.
• 04:11 — The DNA Company’s philosophy: building innovation and accessibility into patient care.
• 06:00 — The history and future role of pharmacogenomics; statistics on efficacy and access.
• 09:17 — New genomics reporting, technology, and app innovations.
• 10:25 — Tracy’s call for a paradigm shift from aggregate medicine to true precision medicine.

Conclusion

Tracy Wood’s appearance on The Digital Executive delivers an impassioned case for functional genomics as the foundation of safer, more personalized healthcare, grounded in both scientific rigor and personal conviction. Her leadership at The DNA Company is propelling precision medicine forward—making life-saving genetic insights increasingly accessible, affordable, and actionable for all.